4.6 Article

PTPRO is a therapeutic target and correlated with immune infiltrates in pancreatic cancer

Journal

JOURNAL OF CANCER
Volume 12, Issue 24, Pages 7445-7453

Publisher

IVYSPRING INT PUBL
DOI: 10.7150/jca.64661

Keywords

PTPRO; prognosis; biomarker; pancreatic cancer; tumor-infiltrating

Categories

Funding

  1. National Natural Science Foundation of China [82003590]
  2. China-Australia Centre for Health Sciences Research [2019GJ07]
  3. Research Funds of Shandong Academy of Medical Science for Young Scholar [2018-32]

Ask authors/readers for more resources

PTPRO may have oncogenic roles in specific cancer types such as pancreatic cancer, blood cancer, and breast cancer. Inhibition of PTPRO can suppress the proliferative abilities of tumor cells, while PTPRO expression promotes immune cell infiltration in pancreatic cancer.
As a member of protein tyrosine phosphatases (PTPs), the protein tyrosine phosphatase receptor type O (PTPRO) has attracted increasing attention for its important roles in cell signaling. Currently, the roles of PTPRO in human cancers remain elusive. Herein, we performed bioinformatic analyses and revealed the potential oncogenic role of PTPRO in specific cancer types. Further in vitro experiments indicated that inhibition of PTPRO suppresses the proliferative abilities of tumor cells in pancreatic cancer, blood cancer, and breast cancer. Moreover, small molecular PTPRO inhibitor could induce cell apoptosis and affect the cell cycle in pancreatic cancer. In addition, PTPRO expression promoted the infiltration of CD8+ T, macrophages, dendritic cells, and neutrophils, in pancreatic cancers. Our findings suggested PTPRO may serve as a potential drug target for pancreatic cancer.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available